{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:46:54Z","timestamp":1789681614818,"version":"4.0.1"},"reference-count":214,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimie"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.biochi.2024.04.009","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T01:29:51Z","timestamp":1713835791000},"page":"54-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Mesenchymal stem cells in autoimmune disease: A systematic review and meta-analysis of pre-clinical studies"],"prefix":"10.1016","volume":"223","author":[{"given":"Hailey N.","family":"Swain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6872-2327","authenticated-orcid":false,"given":"Parker D.","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8947-3028","authenticated-orcid":false,"given":"Bradley A.","family":"Bromet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiden","family":"Barozinksy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacy","family":"Hance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dakota","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1213-2241","authenticated-orcid":false,"given":"Gayla R.","family":"Olbricht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6672-5029","authenticated-orcid":false,"given":"Julie A.","family":"Semon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biochi.2024.04.009_bib1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2217\/rme-2018-0145","article-title":"Nomenclature and heterogeneity: consequences for the use of mesenchymal stem cells in regenerative medicine","volume":"14","author":"Wilson","year":"2019","journal-title":"Regen. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s13287-021-02435-1","article-title":"Characterisation of mesenchymal stromal cells in clinical trial reports: analysis of published descriptors","volume":"12","author":"Wilson","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biochi.2024.04.009_bib3","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/sctm.17-0051","article-title":"Mesenchymal stem cells: time to change the Name","volume":"6","author":"Caplan","year":"2017","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib4","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/aps.2013.50","article-title":"Mesenchymal stem cells: a new trend for cell therapy","volume":"34","author":"Wei","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.biochi.2024.04.009_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biochi.2024.04.009_bib6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/14653240500319234","article-title":"Clarification of the nomenclature for MSC: the International Society for cellular therapy position statement","volume":"7","author":"Horwitz","year":"2005","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biochi.2024.04.009_bib7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41536-019-0083-6","article-title":"Mesenchymal stem cell perspective: cell biology to clinical progress","volume":"4","author":"Pittenger","year":"2019","journal-title":"NPJ Regen. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib8","first-page":"e264","article-title":"Sources and clinical applications of mesenchymal stem cells, Sultan Qaboos univ","volume":"18","author":"Berebichez-Fridman","year":"2018","journal-title":"Med. J."},{"key":"10.1016\/j.biochi.2024.04.009_bib9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s13287-022-02985-y","article-title":"Mesenchymal stem cells and their microenvironment","volume":"13","author":"Liu","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biochi.2024.04.009_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s13770-021-00417-1","article-title":"Sources, characteristics, and therapeutic applications of mesenchymal cells in tissue engineering","volume":"19","author":"Gonzalez-Vilchis","year":"2022","journal-title":"Tissue Eng. Regen. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1177\/0963689719837897","article-title":"The pros and cons of mesenchymal stem cell-based therapies","volume":"28","author":"Musia\u0142-Wysocka","year":"2019","journal-title":"Cell Transplant."},{"key":"10.1016\/j.biochi.2024.04.009_bib12","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.tips.2020.06.009","article-title":"Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential","volume":"41","author":"Song","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biochi.2024.04.009_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.327","article-title":"Mesenchymal stem cells and immunomodulation: current status and future prospects","volume":"7","author":"Gao","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biochi.2024.04.009_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13287-022-02782-7","article-title":"Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases","volume":"13","author":"Jasim","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biochi.2024.04.009_bib15","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/sctm.21-0021","article-title":"Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells","volume":"10","author":"Wang","year":"2021","journal-title":"STEM CELLS Transl. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib16","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1089\/scd.2011.0674","article-title":"Comparative analysis of paracrine factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose, and dermal tissue","volume":"21","author":"Hsiao","year":"2012","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.biochi.2024.04.009_bib17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s12015-012-9365-8","article-title":"Human stromal (mesenchymal) stem cells from bone marrow, adipose tissue and skin exhibit differences in molecular phenotype and differentiation potential","volume":"9","author":"Al-Nbaheen","year":"2013","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.biochi.2024.04.009_bib18","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1634\/stemcells.2005-0342","article-title":"Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue","volume":"24","author":"Kern","year":"2006","journal-title":"Stem Cells Dayt. Ohio"},{"key":"10.1016\/j.biochi.2024.04.009_bib19","author":"Tachida"},{"key":"10.1016\/j.biochi.2024.04.009_bib20","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.celrep.2013.03.041","article-title":"Self-renewing human bone marrow Mesenspheres promote Hematopoietic stem cell expansion","volume":"3","author":"Isern","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.biochi.2024.04.009_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10856-008-3544-9","article-title":"In\u00a0vitro evaluation of freeze-dried bone allografts combined with platelet rich plasma and human bone marrow stromal cells for tissue engineering","volume":"20","author":"Cenni","year":"2009","journal-title":"J.\u00a0Mater. Sci. Mater. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib22","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1007\/s00018-019-03125-1","article-title":"Biological functions of mesenchymal stem cells and clinical implications","volume":"76","author":"Naji","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.biochi.2024.04.009_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13619-022-00146-3","article-title":"Mesenchymal stem cells in the treatment of osteogenesis imperfecta","volume":"12","author":"Lang","year":"2023","journal-title":"Cell Regen."},{"key":"10.1016\/j.biochi.2024.04.009_bib24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fgene.2016.00213","article-title":"Adipose, bone marrow and synovial joint-derived mesenchymal stem cells for cartilage repair","volume":"7","author":"Fellows","year":"2016","journal-title":"Front. Genet."},{"key":"10.1016\/j.biochi.2024.04.009_bib25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4103\/1305-7456.137631","article-title":"Comparison of phenotype and differentiation marker gene expression profiles in human dental pulp and bone marrow mesenchymal stem cells","volume":"8","author":"Ponnaiyan","year":"2014","journal-title":"Eur. J. Dent."},{"key":"10.1016\/j.biochi.2024.04.009_bib26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nm.1905","article-title":"Bone marrow stromal cells attenuate sepsis via prostaglandin E2\u2014dependent reprogramming of host macrophages to increase their interleukin-10 production","volume":"15","author":"N\u00e9meth","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78864-4","article-title":"Intracellular role of IL-6 in mesenchymal stromal cell immunosuppression and proliferation","volume":"10","author":"Dorronsoro","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biochi.2024.04.009_bib28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.reth.2022.07.003","article-title":"Mesenchymal stem cell therapy: a review of clinical trials for multiple sclerosis","volume":"21","author":"Alanazi","year":"2022","journal-title":"Regen. Ther."},{"key":"10.1016\/j.biochi.2024.04.009_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047559","article-title":"Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials","volume":"7","author":"Lalu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biochi.2024.04.009_bib30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3727\/096368915X689622","article-title":"Clinical trials with mesenchymal stem cells: an update","volume":"25","author":"Squillaro","year":"2016","journal-title":"Cell Transplant."},{"key":"10.1016\/j.biochi.2024.04.009_bib31","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1182\/blood-2011-12-400085","article-title":"Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms","volume":"120","author":"Otsuru","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.04.009_bib32","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/jcp.22408","article-title":"Stromal stem cells from adipose tissue and bone marrow of age-matched female donors display distinct Immunophenotypic profiles","volume":"226","author":"Pach\u00f3n-Pe\u00f1a","year":"2011","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.biochi.2024.04.009_bib33","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1089\/ten.teb.2014.0608","article-title":"Human adipose stem cells: from Bench to Bedside","volume":"21","author":"De Francesco","year":"2015","journal-title":"Tissue Eng. Part B Rev."},{"key":"10.1016\/j.biochi.2024.04.009_bib34","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/sctm.16-0337","article-title":"Concise review: fat and Furious: Harnessing the full potential of adipose-derived stromal vascular fraction","volume":"6","author":"Dykstra","year":"2017","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/scrt19","article-title":"Clinical and preclinical translation of cell-based therapies using adipose tissue-derived cells","volume":"1","author":"Gimble","year":"2010","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biochi.2024.04.009_bib36","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jcyt.2013.02.006","volume":"15","author":"Bourin","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biochi.2024.04.009_bib37","article-title":"Harnessing the secretome of adipose-derived stem cells in the treatment of ischemic heart diseases","volume":"10","author":"Li","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biochi.2024.04.009_bib38","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7416493","article-title":"Isolation and Characterization of human synovial fluid-derived mesenchymal stromal cells from popliteal cyst","volume":"2020","author":"Li","year":"2020","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.biochi.2024.04.009_bib39","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9312329","article-title":"Isolation and Characterization of synovial mesenchymal stem cell derived from hip joints: a comparative analysis with a matched control knee group","volume":"2017","author":"Hatakeyama","year":"2017","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.biochi.2024.04.009_bib40","article-title":"Isolation and characterization of synovial mesenchymal stem cells derived from patients with chronic lateral ankle instability: a comparative analysis of synovial fluid, adipose synovium, and fibrous synovium of the ankle joint, orthop","volume":"10","author":"Nakashima","year":"2022","journal-title":"J.\u00a0Sports Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib41","first-page":"1476","article-title":"Synovial fluid mesenchymal stem cells for knee arthritis and cartilage defects: a review of the literature","volume":"34","author":"Fang","year":"2021","journal-title":"J.\u00a0Knee Surg."},{"key":"10.1016\/j.biochi.2024.04.009_bib42","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1002\/1529-0131(199912)42:12<2631::AID-ANR18>3.0.CO;2-H","article-title":"Chondroprogenitor cells of synovial tissue","volume":"42","author":"Nishimura","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biochi.2024.04.009_bib43","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/1529-0131(200108)44:8<1928::AID-ART331>3.0.CO;2-P","article-title":"Multipotent mesenchymal stem cells from adult human synovial membrane","volume":"44","author":"De Bari","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biochi.2024.04.009_bib44","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jcyt.2013.12.003","article-title":"Clonal analysis of synovial fluid stem cells to characterize and identify stable mesenchymal stromal cell\/mesenchymal progenitor cell phenotypes in a porcine model: a cell source with enhanced commitment to the chondrogenic lineage","volume":"16","author":"Ando","year":"2014","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biochi.2024.04.009_bib45","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/0363546514559822","article-title":"Isolation and characterization of human mesenchymal stem cells derived from synovial fluid in patients with osteochondral lesion of the talus","volume":"43","author":"Kim","year":"2015","journal-title":"Am. J. Sports Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib46","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8431053","article-title":"Production of adult human synovial fluid-derived mesenchymal stem cells in stirred-suspension culture","volume":"2018","author":"Jorgenson","year":"2018","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.biochi.2024.04.009_bib47","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6694299","article-title":"Proteomic analysis reveals commonly secreted proteins of mesenchymal stem cells derived from bone marrow, adipose tissue, and synovial membrane to show potential for cartilage regeneration in knee osteoarthritis","volume":"2021","author":"Lee","year":"2021","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.biochi.2024.04.009_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2021.101727","article-title":"Yields of mesenchymal stromal cells from synovial fluid reflect those from synovium in patients with rheumatoid arthritis","volume":"75","author":"Kohno","year":"2022","journal-title":"Tissue Cell"},{"key":"10.1016\/j.biochi.2024.04.009_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.acthis.2020.151550","article-title":"Expression and functional regulation of gap junction protein connexin 43 in dermal mesenchymal stem cells from psoriasis patients","volume":"122","author":"Wang","year":"2020","journal-title":"Acta Histochem."},{"key":"10.1016\/j.biochi.2024.04.009_bib50","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1111\/ijd.13197","article-title":"Expression of pro-angiogenic genes in mesenchymal stem cells derived from dermis of patients with psoriasis","volume":"55","author":"Niu","year":"2016","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.biochi.2024.04.009_bib51","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/jid.2011.355","article-title":"Human dermis harbors distinct mesenchymal stromal cell subsets","volume":"132","author":"Vaculik","year":"2012","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.biochi.2024.04.009_bib52","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12015-009-9094-9","article-title":"Embryonic stem cell marker expression pattern in human mesenchymal stem cells derived from bone marrow, adipose tissue, heart and dermis","volume":"5","author":"Riekstina","year":"2009","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.biochi.2024.04.009_bib53","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/term.2820","article-title":"In\u00a0vitro comparative study of human mesenchymal stromal cells from dermis and adipose tissue for application in skin wound healing","volume":"13","author":"Zomer","year":"2019","journal-title":"J.\u00a0Tissue Eng. Regen. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib54","article-title":"Dermal mesenchymal stem cells (DMSCs) inhibit skin-homing CD8+ T cell activity, a determining factor of vitiligo patients' autologous melanocytes transplantation efficiency","volume":"8","author":"Zhou","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biochi.2024.04.009_bib55","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jaad.2009.09.022","article-title":"Skin mesenchymal stem cells: prospects for clinical dermatology","volume":"63","author":"Sellheyer","year":"2010","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"key":"10.1016\/j.biochi.2024.04.009_bib58","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jcyt.2019.04.003","article-title":"Manufacturing mesenchymal stromal cells for clinical applications: a survey of Good Manufacturing Practices at U.S. academic centers","volume":"21","author":"Phinney","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biochi.2024.04.009_bib59","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.stem.2011.06.008","article-title":"The MSC: an injury drugstore","volume":"9","author":"Caplan","year":"2011","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.biochi.2024.04.009_bib60","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13287-022-02751-0","article-title":"Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review","volume":"13","author":"Li","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biochi.2024.04.009_bib61","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-021-01037-x","article-title":"Challenges and advances in clinical applications of mesenchymal stromal cells","volume":"14","author":"Zhou","year":"2021","journal-title":"J.\u00a0Hematol. Oncol.J Hematol Oncol"},{"key":"10.1016\/j.biochi.2024.04.009_bib62","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nm.3627","article-title":"Translational strategies and challenges in regenerative medicine","volume":"20","author":"Dimmeler","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.650664","article-title":"The current status of mesenchymal stromal cells: controversies, unresolved issues and some promising solutions to improve their therapeutic efficacy","volume":"9","author":"Garc\u00eda-Bernal","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.biochi.2024.04.009_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.891514","article-title":"Safety and clinical efficacy of mesenchymal stem cell treatment in traumatic spinal cord injury, multiple sclerosis and ischemic stroke - a systematic review and meta-analysis","volume":"13","author":"Kvistad","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.biochi.2024.04.009_bib65","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4067\/S0716-97602012000300008","article-title":"Mesenchymal Stem Cell treatment for autoimmune diseases: a critical review","volume":"45","author":"Figueroa","year":"2012","journal-title":"Biol. Res."},{"key":"10.1016\/j.biochi.2024.04.009_bib66","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/13524585211060686","article-title":"Reduced expression of mitochondrial fumarate hydratase in progressive multiple sclerosis contributes to impaired in\u00a0vitro mesenchymal stromal cell-mediated neuroprotection","volume":"28","author":"Sarkar","year":"2022","journal-title":"Mult. Scler. Houndmills Basingstoke Engl."},{"key":"10.1016\/j.biochi.2024.04.009_bib67","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/1352458510371959","article-title":"Characterization of in\u00a0vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis, Mult. Scler","volume":"16","author":"Mallam","year":"2010","journal-title":"Houndmills Basingstoke Engl"},{"key":"10.1016\/j.biochi.2024.04.009_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/4541797","article-title":"Mesenchymal stromal cells from the epidermis and dermis of psoriasis patients: morphology, immunophenotype, differentiation patterns, and regulation of T cell proliferation","volume":"2019","author":"Castro-Manrreza","year":"2019","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.biochi.2024.04.009_bib69","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/ard.2007.076174","article-title":"Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis","volume":"67","author":"Kastrinaki","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biochi.2024.04.009_bib70","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s11033-019-04588-y","article-title":"Mesenchymal stem cell-based therapy for autoimmune diseases: emerging roles of extracellular vesicles","volume":"46","author":"Rad","year":"2019","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.biochi.2024.04.009_bib71","article-title":"Therapeutic effects of mesenchymal stem cells and their derivatives in common skin inflammatory diseases: atopic dermatitis and psoriasis","volume":"14","author":"Yang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biochi.2024.04.009_bib72","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13578-021-00698-y","article-title":"Allogeneic vs. autologous mesenchymal stem\/stromal cells in their medication practice","volume":"11","author":"Li","year":"2021","journal-title":"Cell Biosci."},{"key":"10.1016\/j.biochi.2024.04.009_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102350","article-title":"Emerging role of vitamin D in autoimmune diseases: an update on evidence and therapeutic implications","volume":"18","author":"Murdaca","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.biochi.2024.04.009_bib74","first-page":"205","article-title":"Sex-based differences in autoimmune diseases, Ann. Ist. Super","volume":"52","author":"Ortona","year":"2016","journal-title":"Sanita"},{"key":"10.1016\/j.biochi.2024.04.009_bib75","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6379161","article-title":"Evaluation of the therapeutic potential of mesenchymal stem cells (MSCs) in preclinical models of autoimmune diseases","volume":"2022","author":"Shandil","year":"2022","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.biochi.2024.04.009_bib76","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/intimm\/dxw010","article-title":"Introduction: autoimmunity special issue","volume":"28","author":"Yamamoto","year":"2016","journal-title":"Int. Immunol."},{"key":"10.1016\/j.biochi.2024.04.009_bib77","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jaut.2009.09.008","article-title":"Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases","volume":"33","author":"Cooper","year":"2009","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.biochi.2024.04.009_bib78","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.beha.2011.01.002","article-title":"Mesenchymal stem cells and autoimmune diseases","volume":"24","author":"Dazzi","year":"2011","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.biochi.2024.04.009_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231846","article-title":"Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: real world evidence based on German claims data","volume":"15","author":"Ohlmeier","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.biochi.2024.04.009_bib80","first-page":"1","article-title":"Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy","volume":"19","author":"Ghasemi","year":"2017","journal-title":"Cell J"},{"key":"10.1016\/j.biochi.2024.04.009_bib81","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuron.2006.09.011","article-title":"The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration","volume":"52","author":"Hauser","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.biochi.2024.04.009_bib82","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1212\/01.wnl.0000194259.90286.fe","article-title":"Disability progression in multiple sclerosis is slower than previously reported","volume":"66","author":"Tremlett","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.biochi.2024.04.009_bib83","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/j.pain.0000000000001429","article-title":"The association between multiple sclerosis and pain medications","volume":"160","author":"Burkill","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.biochi.2024.04.009_bib84","first-page":"175","article-title":"Multiple sclerosis review, P T Peer-Rev. J. Formul","volume":"37","author":"Goldenberg","year":"2012","journal-title":"Manag."},{"key":"10.1016\/j.biochi.2024.04.009_bib85","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2174\/157015911796557911","article-title":"Multiple sclerosis: pathogenesis and treatment","volume":"9","author":"Loma","year":"2011","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.biochi.2024.04.009_bib86","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.biochi.2024.04.009_bib87","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/scrt391","article-title":"Comparison of human adult stem cells from adipose tissue and bone marrow in the treatment of experimental autoimmune encephalomyelitis","volume":"5","author":"Semon","year":"2014","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biochi.2024.04.009_bib88","doi-asserted-by":"crossref","first-page":"8662","DOI":"10.3390\/ijms21228662","article-title":"Mesenchymal stem cells in multiple sclerosis: recent evidence from pre-clinical to clinical studies","volume":"21","author":"Gugliandolo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biochi.2024.04.009_bib89","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1093\/brain\/awaa333","article-title":"Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis","volume":"143","author":"Petrou","year":"2020","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.biochi.2024.04.009_bib90","first-page":"866","article-title":"Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: clinical, ophthalmological and radiological assessments of safety and efficacy, CNS Neurosci","volume":"23","author":"Dahbour","year":"2017","journal-title":"Ther"},{"key":"10.1016\/j.biochi.2024.04.009_bib91","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s13287-021-02477-5","article-title":"A\u00a0focus on allogeneic mesenchymal stromal cells as a versatile therapeutic tool for treating multiple sclerosis","volume":"12","author":"Shokati","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biochi.2024.04.009_bib92","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12967-018-1433-7","article-title":"Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis","volume":"16","author":"Riordan","year":"2018","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib93","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1474-4422(11)70305-2","article-title":"Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study","volume":"11","author":"Connick","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biochi.2024.04.009_bib94","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1745-6215-12-62","article-title":"The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments","volume":"12","author":"Connick","year":"2011","journal-title":"Trials"},{"key":"10.1016\/j.biochi.2024.04.009_bib95","doi-asserted-by":"crossref","first-page":"e928","DOI":"10.1212\/NXI.0000000000000928","article-title":"Mesenchymal stem cell-derived neural progenitors in progressive MS: two-year follow-up of a phase I study","volume":"8","author":"Harris","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.biochi.2024.04.009_bib96","first-page":"1187","article-title":"Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis, Arch","volume":"67","author":"Karussis","year":"2010","journal-title":"Neurol."},{"key":"10.1016\/j.biochi.2024.04.009_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195891","article-title":"Research Group Study EudraCT 2008-004015-35, Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: a triple blinded, placebo controlled, randomized phase I\/II safety and feasibility study","volume":"13","author":"Fern\u00e1ndez","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.biochi.2024.04.009_bib98","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pop.2018.02.010","article-title":"Early diagnosis and treatment of rheumatoid arthritis","volume":"45","author":"Littlejohn","year":"2018","journal-title":"Prim. Care"},{"key":"10.1016\/j.biochi.2024.04.009_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102400","article-title":"The etiology of rheumatoid arthritis","volume":"110","author":"Scherer","year":"2020","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.biochi.2024.04.009_bib100","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/art.24405","article-title":"Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells","volume":"60","author":"Gonz\u00e1lez","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biochi.2024.04.009_bib101","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nbt.2816","article-title":"Mesenchymal stem cells: immune evasive, not immune privileged","volume":"32","author":"Ankrum","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biochi.2024.04.009_bib102","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/01.TP.0000082540.43730.80","article-title":"Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells","volume":"76","author":"Rasmusson","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.biochi.2024.04.009_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103427","article-title":"Mesenchymal stem\/stromal cell-based therapy for the treatment of rheumatoid arthritis: an update on preclinical studies","volume":"69","author":"Lopez-Santalla","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biochi.2024.04.009_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111592","article-title":"Mesenchymal stem cell-based therapy for rheumatoid arthritis","volume":"22","author":"Sarsenova","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biochi.2024.04.009_bib105","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2015-208918","article-title":"Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib\/IIa clinical trial","volume":"76","author":"\u00c1lvaro-Gracia","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biochi.2024.04.009_bib106","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1089\/scd.2013.0023","article-title":"Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy","volume":"22","author":"Wang","year":"2013","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.biochi.2024.04.009_bib107","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/sctm.18-0031","article-title":"Intravenous infusion of umbilical cord blood-derived mesenchymal stem cells in rheumatoid arthritis: a phase ia clinical trial","volume":"7","author":"Park","year":"2018","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib108","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.biopha.2018.11.056","article-title":"Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: a successful clinical trial in Iran","volume":"109","author":"Ghoryani","year":"2019","journal-title":"Biomed. Pharmacother. Biomedecine Pharmacother."},{"key":"10.1016\/j.biochi.2024.04.009_bib109","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12967-018-1541-4","article-title":"Serum IFN-\u03b3 levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis","volume":"16","author":"Yang","year":"2018","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.631291","article-title":"Recent developments in clinical applications of mesenchymal stem cells in the treatment of rheumatoid arthritis and osteoarthritis","volume":"12","author":"Hwang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biochi.2024.04.009_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102755","article-title":"Mesenchymal stromal cells for systemic sclerosis treatment","volume":"20","author":"Farge","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.biochi.2024.04.009_bib112","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3389\/fimmu.2018.02013","article-title":"Mesenchymal stromal cells based therapy in systemic sclerosis: rational and challenges","volume":"9","author":"Peltzer","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biochi.2024.04.009_bib113","series-title":"Scleroderma, in: StatPearls","author":"Odonwodo","year":"2023"},{"key":"10.1016\/j.biochi.2024.04.009_bib114","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5114\/reum.2016.60220","article-title":"Scleroderma of geriatric age and scleroderma-like paraneoplastic syndrome \u2013 description of two cases","volume":"54","author":"Marek","year":"2016","journal-title":"Reumatologia"},{"key":"10.1016\/j.biochi.2024.04.009_bib115","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/art.1780390814","article-title":"Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype","volume":"39","author":"Arnett","year":"1996","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biochi.2024.04.009_bib116","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.3390\/jcm9092687","article-title":"The pathogenesis of systemic sclerosis: an understanding based on a common pathologic cascade across multiple organs and additional organ-specific pathologies","volume":"9","author":"Asano","year":"2020","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib117","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s12016-021-08889-8","article-title":"Current concepts on the pathogenesis of systemic sclerosis","volume":"64","author":"Truchetet","year":"2023","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.biochi.2024.04.009_bib118","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5114\/reum.2019.87619","article-title":"Systemic sclerosis \u2013 multidisciplinary disease: clinical features and treatment","volume":"57","author":"Sobolewski","year":"2019","journal-title":"Reumatologia"},{"key":"10.1016\/j.biochi.2024.04.009_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102526","article-title":"Bi-directional communication: conversations between fibroblasts and immune cells in systemic sclerosis","volume":"113","author":"Worrell","year":"2020","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.biochi.2024.04.009_bib120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41420-022-01264-2","article-title":"Mesenchymal stem cells alleviate systemic sclerosis by inhibiting the recruitment of pathogenic macrophages","volume":"8","author":"Gong","year":"2022","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.biochi.2024.04.009_bib121","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.biochi.2024.04.009_bib122","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","article-title":"The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies","volume":"56","author":"Rees","year":"2017","journal-title":"Rheumatol. Oxf. Engl."},{"key":"10.1016\/j.biochi.2024.04.009_bib123","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/BOR.0000000000000480","article-title":"Epidemiology of systemic lupus erythematosus: an update","volume":"30","author":"Stojan","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.biochi.2024.04.009_bib124","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000513741","article-title":"An update for mesenchymal stem cell therapy in lupus nephritis","volume":"7","author":"Li","year":"2021","journal-title":"Kidney Dis."},{"key":"10.1016\/j.biochi.2024.04.009_bib125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2478\/rir-2022-0011","article-title":"Stem cell therapy in lupus","volume":"3","author":"Yuan","year":"2022","journal-title":"Rheumatol. Immunol. Res."},{"key":"10.1016\/j.biochi.2024.04.009_bib126","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrrheum.2016.137","article-title":"The global burden of SLE: prevalence, health disparities and socioeconomic impact","volume":"12","author":"Carter","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.biochi.2024.04.009_bib127","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.mayocp.2019.09.012","article-title":"Sex differences in systemic lupus erythematosus: epidemiology, clinical considerations, and disease pathogenesis","volume":"95","author":"Nusbaum","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.biochi.2024.04.009_bib128","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11926-021-00985-0","article-title":"Systemic lupus erythematosus in children and young people, curr","volume":"23","author":"Charras","year":"2021","journal-title":"Rheumatol. Rep."},{"key":"10.1016\/j.biochi.2024.04.009_bib129","doi-asserted-by":"crossref","first-page":"ITC81","DOI":"10.7326\/AITC202006020","article-title":"Systemic lupus erythematosus","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102870","article-title":"Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies","volume":"132","author":"Li","year":"2022","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.biochi.2024.04.009_bib131","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.3390\/ijms24076578","article-title":"Advances in the pathogenesis and treatment of systemic lupus erythematosus","volume":"24","author":"Accapezzato","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biochi.2024.04.009_bib132","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1118180","article-title":"Editorial: systemic lupus erythematosus - predisposition factors, pathogenesis, diagnosis, treatment and disease models","volume":"13","author":"Nandakumar","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biochi.2024.04.009_bib133","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.3390\/ijms23105317","article-title":"Impact of adipose-derived mesenchymal stem cells (ASCs) of rheumatic disease patients on T helper cell differentiation","volume":"23","author":"Kuca-Warnawin","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biochi.2024.04.009_bib134","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13287-022-03002-y","article-title":"Mesenchymal stem cell transplantation alleviated atherosclerosis in systemic lupus erythematosus through reducing MDSCs","volume":"13","author":"Yao","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biochi.2024.04.009_bib135","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/stem.68","article-title":"Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans","volume":"27","author":"Sun","year":"2009","journal-title":"Stem Cells Dayt. Ohio"},{"key":"10.1016\/j.biochi.2024.04.009_bib136","article-title":"Mesenchymal stem cell therapy: hope for patients with systemic lupus erythematosus","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biochi.2024.04.009_bib137","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1177\/0961203318804922","article-title":"Therapeutic potential of allogeneic mesenchymal stromal cells transplantation for lupus nephritis","volume":"27","author":"Barbado","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.biochi.2024.04.009_bib138","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1177\/09612033221111957","article-title":"Safety and tolerability of bone marrow-derived mesenchymal stem cells in lupus animal models and a phase I clinical trial in humans","volume":"31","author":"Chun","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.biochi.2024.04.009_bib139","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/qjmed\/hcu033","article-title":"Mesenchymal stem cells, autoimmunity and rheumatoid arthritis","volume":"107","author":"El-Jawhari","year":"2014","journal-title":"QJM Mon. J. Assoc. Physicians"},{"key":"10.1016\/j.biochi.2024.04.009_bib140","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.3727\/096368911X582769c","article-title":"Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience","volume":"22","author":"Wang","year":"2013","journal-title":"Cell Transplant."},{"key":"10.1016\/j.biochi.2024.04.009_bib141","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000704","article-title":"Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE","volume":"9","author":"Kamen","year":"2022","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib142","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3727\/096368917X694822","article-title":"Phenotypical and functional characteristics of in\u00a0vitro-expanded adipose-derived mesenchymal stromal cells from patients with systematic sclerosis","volume":"26","author":"Capelli","year":"2017","journal-title":"Cell Transplant."},{"key":"10.1016\/j.biochi.2024.04.009_bib143","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/ard.2007.071233","article-title":"Phenotypical and functional characteristics of in\u00a0vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis","volume":"67","author":"Larghero","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biochi.2024.04.009_bib144","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.biochi.2024.04.009_bib145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int. J. Soc. Res. Methodol."},{"key":"10.1016\/j.biochi.2024.04.009_bib146","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.biochi.2024.04.009_bib147","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s10875-023-01511-w","article-title":"Inherited CD19 deficiency does not impair plasma cell formation or response to CXCL12","volume":"43","author":"Walker","year":"2023","journal-title":"J.\u00a0Clin. Immunol."},{"key":"10.1016\/j.biochi.2024.04.009_bib148","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.4049\/jimmunol.2101056","article-title":"Preclinical analysis of candidate anti-human CD79 therapeutic antibodies using a humanized CD79 mouse model","volume":"208","author":"Wemlinger","year":"2022","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.biochi.2024.04.009_bib149","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3727\/096368913X675142","article-title":"Bone marrow mesenchymal stromal cells isolated from multiple sclerosis patients have distinct gene expression profile and decreased suppressive function compared with healthy counterparts","volume":"24","author":"de Oliveira","year":"2015","journal-title":"Cell Transplant."},{"key":"10.1016\/j.biochi.2024.04.009_bib150","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/826182","article-title":"Gene expression profile reveals abnormalities of multiple signaling pathways in mesenchymal stem cell derived from patients with systemic lupus erythematosus","volume":"2012","author":"Tang","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.biochi.2024.04.009_bib151","article-title":"Induction of apoptosis coupled to endoplasmic reticulum stress through regulation of CHOP and JNK in bone marrow mesenchymal stem cells from patients with systemic lupus erythematosus","volume":"2015","author":"Guo","year":"2015","journal-title":"J.\u00a0Immunol. Res."},{"key":"10.1016\/j.biochi.2024.04.009_bib152","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13287-017-0690-3","article-title":"Combined platelet-rich plasma and lipofilling treatment provides great improvement in facial skin-induced lesion regeneration for scleroderma patients","volume":"8","author":"Virz\u00ec","year":"2017","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biochi.2024.04.009_bib153","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/sctm.18-0045","article-title":"Dysregulation of mesenchymal stromal cell antioxidant responses in progressive multiple sclerosis","volume":"7","author":"Redondo","year":"2018","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib154","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/1352458517711276","article-title":"Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in\u00a0vitro","volume":"24","author":"Redondo","year":"2018","journal-title":"Mult. Scler. Houndmills Basingstoke Engl."},{"key":"10.1016\/j.biochi.2024.04.009_bib155","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/art.22698","article-title":"Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis","volume":"56","author":"Cipriani","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biochi.2024.04.009_bib156","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10456-013-9338-9","article-title":"Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine","volume":"16","author":"Cipriani","year":"2013","journal-title":"Angiogenesis"},{"key":"10.1016\/j.biochi.2024.04.009_bib157","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.3390\/jcm8111979","article-title":"Adipose-derived stem cells from systemic sclerosis patients maintain pro-angiogenic and antifibrotic paracrine effects in\u00a0vitro","volume":"8","author":"Velier","year":"2019","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib158","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s13287-021-02453-z","article-title":"Chronic inflammation-induced senescence impairs immunomodulatory properties of synovial fluid mesenchymal stem cells in rheumatoid arthritis","volume":"12","author":"Lee","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biochi.2024.04.009_bib159","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1089\/scd.2011.0447","article-title":"Enhanced apoptosis and senescence of bone-marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus","volume":"21","author":"Li","year":"2012","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.biochi.2024.04.009_bib160","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/abbs\/gmw134","article-title":"JAK-STAT signaling mediates the senescence of bone marrow-mesenchymal stem cells from systemic lupus erythematosus patients","volume":"49","author":"Ji","year":"2017","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.biochi.2024.04.009_bib161","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/134243","article-title":"p53\/p21 Pathway involved in mediating cellular senescence of bone marrow-derived mesenchymal stem cells from systemic lupus erythematosus patients","volume":"2013","author":"Gu","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.biochi.2024.04.009_bib162","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11010-013-1866-5","article-title":"Wnt\/\u03b2-catenin signaling mediates the senescence of bone marrow-mesenchymal stem cells from systemic lupus erythematosus patients through the p53\/p21 pathway","volume":"387","author":"Gu","year":"2014","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.biochi.2024.04.009_bib163","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.cellsig.2012.07.012","article-title":"Upregulation of p16INK4A promotes cellular senescence of bone marrow-derived mesenchymal stem cells from systemic lupus erythematosus patients","volume":"24","author":"Gu","year":"2012","journal-title":"Cell. Signal."},{"key":"10.1016\/j.biochi.2024.04.009_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2019.05.012","article-title":"Bone marrow mesenchymal stem cells from patients with SLE maintain an interferon signature during in\u00a0vitro culture","volume":"132","author":"Gao","year":"2020","journal-title":"Cytokine"},{"key":"10.1016\/j.biochi.2024.04.009_bib165","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1177\/0961203310361482","article-title":"Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus","volume":"19","author":"Nie","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.biochi.2024.04.009_bib166","first-page":"211","article-title":"Alterations of ROS pathways in scleroderma begin at stem cell level","volume":"27","author":"Orciani","year":"2013","journal-title":"J.\u00a0Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.biochi.2024.04.009_bib167","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0961203306075793","article-title":"Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus","volume":"16","author":"Sun","year":"2007","journal-title":"Lupus"},{"key":"10.1016\/j.biochi.2024.04.009_bib168","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/art.40142","article-title":"Bone marrow\u2013derived mesenchymal stem cells from patients with systemic lupus erythematosus have a senescence-associated secretory phenotype mediated by a mitochondrial antiviral signaling protein\u2013interferon-\u03b2 feedback loop","volume":"69","author":"Gao","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.biochi.2024.04.009_bib169","doi-asserted-by":"crossref","first-page":"85","DOI":"10.15283\/ijsc20073","article-title":"Dysregulated dermal mesenchymal stem cell proliferation and differentiation interfered by glucose metabolism in psoriasis","volume":"14","author":"Zhao","year":"2021","journal-title":"Int. J. Stem Cells"},{"key":"10.1016\/j.biochi.2024.04.009_bib170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13287-016-0444-7","article-title":"Characteristics of human adipose derived stem cells in scleroderma in comparison to sex and age matched normal controls: implications for regenerative medicine","volume":"8","author":"Griffin","year":"2017","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biochi.2024.04.009_bib171","article-title":"Association of TNF-\u03b1 with impaired migration capacity of mesenchymal stem cells in patients with systemic lupus erythematosus","volume":"2014","author":"Geng","year":"2014","journal-title":"J.\u00a0Immunol. Res."},{"key":"10.1016\/j.biochi.2024.04.009_bib172","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/sctm.19-0073","article-title":"Mesenchymal stromal cells anno 2019: dawn of the therapeutic era? Concise review","volume":"8","author":"Hoogduijn","year":"2019","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib173","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-4939-3578-9_5","article-title":"The gene expression Omnibus database","volume":"1418","author":"Clough","year":"2016","journal-title":"Methods Mol. Biol. Clifton NJ"},{"key":"10.1016\/j.biochi.2024.04.009_bib174","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ebiom.2015.12.020","article-title":"A\u00a0clinical indications prediction scale based on TWIST1 for human mesenchymal stem cells","volume":"4","author":"Boregowda","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biochi.2024.04.009_bib175","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int. Immunol."},{"key":"10.1016\/j.biochi.2024.04.009_bib176","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005212","article-title":"Translational upregulation of an individual p21Cip1 transcript variant by GCN2 regulates cell proliferation and survival under nutrient stress","volume":"11","author":"Lehman","year":"2015","journal-title":"PLoS Genet."},{"key":"10.1016\/j.biochi.2024.04.009_bib177","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s42358-023-00320-4","article-title":"TP53 and p21 (CDKN1A) polymorphisms and the risk of systemic lupus erythematosus","volume":"63","author":"Macedo","year":"2023","journal-title":"Adv. Rheumatol."},{"key":"10.1016\/j.biochi.2024.04.009_bib178","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.matbio.2023.06.007","article-title":"TSG6 hyaluronan matrix remodeling dampens the inflammatory response during colitis","volume":"121","author":"Albtoush","year":"2023","journal-title":"Matrix Biol."},{"key":"10.1016\/j.biochi.2024.04.009_bib179","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.18632\/oncotarget.26894","article-title":"Interleukin 1 is a key driver of inflammatory bowel disease-demonstration in a murine IL-1Ra knockout model","volume":"10","author":"Dosh","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.biochi.2024.04.009_bib180","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1097\/MIB.0b013e318281f506","article-title":"Granulocyte-macrophage colony-stimulating factor auto-antibodies: a marker of aggressive crohn's disease","volume":"19","author":"Gathungu","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.biochi.2024.04.009_bib181","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1517\/14728222.2014.930440","article-title":"SDF-1 signaling: a promising target in rheumatic diseases","volume":"18","author":"Villalvilla","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.biochi.2024.04.009_bib182","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1517\/14728220903196761","article-title":"Targeting the CXCR4\/CXCL12 axis in systemic lupus erythematosus","volume":"13","author":"Chong","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.biochi.2024.04.009_bib183","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jneuroim.2015.11.021","article-title":"New insights into the role of stromal cell-derived factor 1 (SDF-1\/CXCL12) in the pathophysiology of multiple sclerosis","volume":"290","author":"Khorramdelazad","year":"2016","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.biochi.2024.04.009_bib184","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/ard.2008.098277","article-title":"Association between a stromal cell-derived factor 1 (SDF-1\/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis","volume":"68","author":"Manetti","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biochi.2024.04.009_bib185","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.3389\/fimmu.2019.01265","article-title":"Roles of GM-CSF in the pathogenesis of autoimmune diseases: an update","volume":"10","author":"Lotfi","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biochi.2024.04.009_bib186","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3109\/08820139709088547","article-title":"Interleukin-1 and interleukin-1 receptor antagonist in systemic lupus erythematosus","volume":"26","author":"Chang","year":"1997","journal-title":"Immunol. Invest."},{"key":"10.1016\/j.biochi.2024.04.009_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2022.114812","article-title":"Immunologic profiling in schizophrenia and rheumatoid arthritis","volume":"317","author":"Eaton","year":"2022","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biochi.2024.04.009_bib188","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083835","article-title":"Interleukin-1\u03b2 and interleukin-1 receptor antagonist appear in grey matter additionally to white matter lesions during experimental multiple sclerosis","volume":"8","author":"Prins","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biochi.2024.04.009_bib189","article-title":"Tumor necrosis factor-alpha stimulated gene-6: a biomarker reflecting disease activity in rheumatoid arthritis","volume":"36","author":"Hu","year":"2022","journal-title":"J.\u00a0Clin. Lab. Anal."},{"key":"10.1016\/j.biochi.2024.04.009_bib190","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/561098","article-title":"Enhancing the migration ability of mesenchymal stromal cells by targeting the SDF-1\/CXCR4 axis","volume":"2013","author":"Marquez-Curtis","year":"2013","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.biochi.2024.04.009_bib191","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s13770-018-0163-5","article-title":"GM-CSF enhances mobilization of bone marrow mesenchymal stem cells via a CXCR4-medicated mechanism","volume":"16","author":"Kim","year":"2018","journal-title":"Tissue Eng. Regen. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib192","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/biof.1587","article-title":"The role of Interleukin 1 receptor antagonist in mesenchymal stem cell-based tissue repair and regeneration","volume":"46","author":"Harrell","year":"2020","journal-title":"Biofactors"},{"key":"10.1016\/j.biochi.2024.04.009_bib193","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1182\/blood-2010-12-327353","article-title":"Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2\/NF-\u03baB signaling in resident macrophages","volume":"118","author":"Choi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.biochi.2024.04.009_bib194","doi-asserted-by":"crossref","first-page":"9879","DOI":"10.3390\/ijms22189879","article-title":"The kynurenine pathway-new linkage between innate and adaptive immunity in autoimmune endocrinopathies","volume":"22","author":"Krupa","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biochi.2024.04.009_bib195","article-title":"Prophylactic and therapeutic effect of kynurenine for experimental autoimmune encephalomyelitis (EAE) disease","volume":"15","author":"Sundaram","year":"2022","journal-title":"Int. J. Tryptophan Res. IJTR"},{"key":"10.1016\/j.biochi.2024.04.009_bib196","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12974-020-01844-y","article-title":"Kynurenine pathway modulation reverses the experimental autoimmune encephalomyelitis mouse disease progression","volume":"17","author":"Sundaram","year":"2020","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.biochi.2024.04.009_bib197","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jare.2022.05.012","article-title":"Immunomodulatory properties of mesenchymal stromal\/stem cells: the link with metabolism","volume":"45","author":"Li","year":"2023","journal-title":"J.\u00a0Adv. Res."},{"key":"10.1016\/j.biochi.2024.04.009_bib198","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/iid3.236","article-title":"ATP promotes immunosuppressive capacities of mesenchymal stromal cells by enhancing the expression of indoleamine dioxygenase","volume":"6","author":"Lotfi","year":"2018","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.biochi.2024.04.009_bib199","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.jcyt.2013.05.011","article-title":"Secreted galectin-3 as a possible biomarker for the immunomodulatory potential of human umbilical cord mesenchymal stromal cells","volume":"15","author":"Liu","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.biochi.2024.04.009_bib200","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102847","article-title":"Emerging role of galectin family in inflammatory autoimmune diseases","volume":"20","author":"Xu","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.biochi.2024.04.009_bib201","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.3390\/jcm9103312","article-title":"Diagnostic power of galectin-3 in rheumatic diseases","volume":"9","author":"Gruszewska","year":"2020","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.biochi.2024.04.009_bib202","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijcard.2016.12.140","article-title":"Galectin-3 is an independent predictor of survival in systemic sclerosis","volume":"233","author":"Faludi","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.biochi.2024.04.009_bib203","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13287-017-0691-2","article-title":"Galectin-1 and galectin-3 expression in equine mesenchymal stromal cells (MSCs), synovial fibroblasts and chondrocytes, and the effect of inflammation on MSC motility","volume":"8","author":"Reesink","year":"2017","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biochi.2024.04.009_bib204","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00000441-200404000-00006","article-title":"Type II collagen autoimmunity in rheumatoid arthritis","volume":"327","author":"Kim","year":"2004","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.biochi.2024.04.009_bib205","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev.immunol.24.021605.090737","article-title":"Transforming growth FACTOR-\u03b2 regulation of immune responses","volume":"24","author":"Li","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.biochi.2024.04.009_bib206","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022202","article-title":"TGF-\u0392 family signaling in mesenchymal differentiation","volume":"10","author":"Grafe","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.biochi.2024.04.009_bib207","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cytogfr.2018.06.002","article-title":"TGF-\u03b2 and mesenchymal stromal cells in regenerative medicine, autoimmunity and cancer","volume":"43","author":"de Ara\u00fajo Farias","year":"2018","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.biochi.2024.04.009_bib208","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jdermsci.2007.05.014","article-title":"Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis","volume":"49","author":"Ihn","year":"2008","journal-title":"J.\u00a0Dermatol. Sci."},{"key":"10.1016\/j.biochi.2024.04.009_bib209","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/096120339300200402","article-title":"Role of transforming growth factor beta (TGF beta) in systemic autoimmunity","volume":"2","author":"Del Giudice","year":"1993","journal-title":"Lupus"},{"key":"10.1016\/j.biochi.2024.04.009_bib210","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s13287-020-01789-2","article-title":"A\u00a0glance on the role of actin in osteogenic and adipogenic differentiation of mesenchymal stem cells","volume":"11","author":"Khan","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biochi.2024.04.009_bib211","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/ten.teb.2019.0250","article-title":"Lineage commitment, signaling pathways, and the cytoskeleton systems in mesenchymal stem cells","volume":"26","author":"Saidova","year":"2020","journal-title":"Tissue Eng. Part B Rev."},{"key":"10.1016\/j.biochi.2024.04.009_bib212","article-title":"The remodelling of actin composition as a hallmark of cancer, Transl","volume":"14","author":"Suresh","year":"2021","journal-title":"Oncol."},{"key":"10.1016\/j.biochi.2024.04.009_bib213","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.14336\/AD.2023.0208","article-title":"Mesenchymal stem cell senescence during aging:from mechanisms to rejuvenation strategies","volume":"14","author":"Jiang","year":"2023","journal-title":"Aging Dis"},{"key":"10.1016\/j.biochi.2024.04.009_bib214","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13287-022-02822-2","article-title":"Potential pre-activation strategies for improving therapeutic efficacy of mesenchymal stem cells: current status and future prospects","volume":"13","author":"Li","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biochi.2024.04.009_bib215","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.310","article-title":"Hypoxia-induced expression of cellular prion protein improves the therapeutic potential of mesenchymal stem cells","volume":"7","author":"Han","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biochi.2024.04.009_bib216","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1089\/ten.2006.12.2141","article-title":"Visual histological grading system for the evaluation of in\u00a0vitro-generated neocartilage","volume":"12","author":"Grogan","year":"2006","journal-title":"Tissue Eng."}],"container-title":["Biochimie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300908424000841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300908424000841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T02:15:29Z","timestamp":1720577729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300908424000841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":214,"alternative-id":["S0300908424000841"],"URL":"https:\/\/doi.org\/10.1016\/j.biochi.2024.04.009","relation":{},"ISSN":["0300-9084"],"issn-type":[{"value":"0300-9084","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mesenchymal stem cells in autoimmune disease: A systematic review and meta-analysis of pre-clinical studies","name":"articletitle","label":"Article Title"},{"value":"Biochimie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biochi.2024.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. and Soci\u00e9t\u00e9 Fran\u00e7aise de Biochimie et Biologie Mol\u00e9culaire (SFBBM). All rights reserved.","name":"copyright","label":"Copyright"}]}}